Tag: IMGN632
Study Reinforces the Potential of Pivekimab Sunirine as a Novel Addition...
Initial safety and efficacy findings from an open-label, dose-escalation and expansion cohorts of the Phase 1b/2 study of pivekimab sunirine (IMGN632), a CD123 (Interleukin-3 alpha...
ImmunoGen and Gilead Sciences to Jointly Evaluate Pivekimab Sunirine + Magrolimab...
Gilead Sciences snf ImmunoGen have agreed to jointly evaluate the safety and anti-leukemia activity of pivekimab sunirine (IMGN632), a CD123 (Interleukin-3 alpha chain/IL-3 Rα) -targeting...
IMGN632 Receives Breakthrough Therapy Designation in Relapsed or Refractory Blastic Plasmacytoid...
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for IMGN632, a novel CD123-targeting Antibody-drug Conjugate (ADC), for the treatment of...
ImmunoGen Initiates Pivotal Trial Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
Biotech company ImmunoGen, leveraging the targeting ability of antibodies to deliver cytotoxic drugs directly to cancer cells by developing the next generation of antibody-drug...
ASH 2019: Findings from Phase I Study of IMGN632 Shows Potential...
New safety and efficacy findings from the dose escalation and expansion of the first-in-human trial of IMGN632 in patients with relapsed/refractory acute myeloid leukemia...
ImmunoGen to Prioritize Continued Development of Mirvetuximab Soravtansine
Waltham, Massachusetts, based ImmunoGen, expanding field of antibody-drug conjugates (ADCs) with the development of the next generation of targeted anti-cancer agents, has completed an...
Amid Significant Progress, Robust Growth and Advancing Pipeline — Immunogen Closes...
A leader in the expanding field of antibody-drug conjugates or ADCs for the treatment of cancer, Immunogen last week highlighted some of the company's...
Antibody-Drug Conjugates at the 59th American Society of Hematology Annual...
This year, in Atlanta, the South's largest and most vibrant city, the 59th annual meeting and exposition of the American Society of Hematology, to...
Jazz Pharmaceuticals and ImmunoGen Sign Development and Commercialization Agreement
Jazz Pharmaceuticals, an international biopharmaceutical company focusing on address unmet medical needs and ImmunoGen, a clinical-stage biotechnology company developing targeted cancer therapeutics using its proprietary antibody-drug conjugate...
IMGN632, a Novel CD123-Targeting Antibody-drug Conjugate, Demonstrates Activity in Acute Myeloid...
Preclinical data on IMGN632, a novel CD123-targeting antibody-drug conjugate being developed by ImmunoGen, presented at the 58th American Society of Hematology (ASH) Annual Meeting...
